Posted on 16/06/2010 in Pharmaceutical Company Product News Lilly has published positive new clinical trial data from a comparative study of Bydureon, its investigational therapy for type 2 diabetes.
The company, in association with partners Amylin and Alkermes, conducted a 26-week study in order to compare the efficacy of its injectable treatment to the oral medications Januvia, Actos and metformin.
It was found that patients using Bydureon were able to meet an optimal blood sugar level of less than seven per cent, while also experiencing better performance in terms of weight loss than any other treatment.
Dr Orville Kolterman, senior vice-president and chief medical officer at Amylin Pharmaceuticals, said the treatment was able to help patients meet glucose control targets recommended by the American Diabetes Association.
He added: "The combination of efficacy, tolerability, and once weekly dosing in this monotherapy setting further supports the potential role Bydureon can play in helping patients and physicians manage type 2 diabetes."
Earlier this month, Lilly won the Community Investment award at the Global Business Coalition Awards for Excellence in Business Action, honouring its efforts to combat tuberculosis in China.Other news stories from 16/06/2010
Read more in the Zenopa News Archive
How this news is generated
|
